Also known as: PASI
FDA approved roflumilast cream 0.3% (Zoryve) for plaque psoriasis in children age 2+, the first once-daily steroid-free topical for that group. A meta-analysis found it improved IGA scores and was well tolerated.
In the BE RADIANT phase 3b trial, bimekizumab provided greater and durable improvements in patient-reported symptoms, skin clearance, and quality of life over 3 years compared with secukinumab in moderate to severe plaque psoriasis. At week 4, significantly more patients on bimekizumab achieved complete absence of itching, skin pain, and scaling. The benefits were sustained through 3 years, including after patients switched from secukinumab.
Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
